A 52-week, Phase III, Open-label, Multi-center Study to Evaluate Efficacy and Safety of GSK1278863 in Japanese Non-dialysis and Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Daprodustat (Primary) ; Methoxy polyethylene glycol-epoetin beta
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 29 Nov 2017 Planned number of patients changed from 320 to 336.
- 29 Nov 2017 Planned End Date changed from 1 Jul 2018 to 25 Oct 2018.
- 29 Nov 2017 Planned primary completion date changed from 1 Jul 2018 to 25 Oct 2018.